BioPharma Resources

Drug Trial Radar · NCT07140393

A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

An Open, Multicenter Phase IB/II Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 28, 2025

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Sponsor type
Industry
First posted
Aug 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.

Conditions

  • Solid Tumor

Interventions

  • HRS-4508+ CapecitabineDrug

    HRS-4508+ Capecitabine

  • HRS-4508+ TrastuzumabDrug

    HRS-4508+ Trastuzumab

  • HRS-4508+ Trastuzumab+ PertuzumabDrug

    HRS-4508+ Trastuzumab+ Pertuzumab

  • HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxelDrug

    HRS-4508+ Trastuzumab+ Pertuzumab+ Nab-paclitaxel

  • HRS-4508+ Trastuzumab + Nab-paclitaxelDrug

    HRS-4508+ Trastuzumab + Nab-paclitaxel

  • HRS-4508+ Trastuzumab+ CapecitabineDrug

    HRS-4508+ Trastuzumab+ Capecitabine

  • Trastuzumab+ CapecitabineDrug

    Trastuzumab+ Capecitabine

  • Trastuzumab+ PertuzumabDrug

    Trastuzumab+ Pertuzumab

  • HRS-4508+SHR-A1811Drug

    HRS-4508+SHR-A1811

  • HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ CarboplatinDrug

    HRS-4508+ Trastuzumab+ Pertuzumab+ Docetaxel+ Carboplatin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HRS4508 DLTTime frame: 3 weeks
  2. HRS4508 MTDTime frame: 12 weeks
  3. HRS4508 RP2DTime frame: 12 weeks
  4. The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)Time frame: 2 years
  5. Objective response rate (ORR)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.